Company intelligence / Profile preview

RongCan (Shanghai) Biotech

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Rongcan Biotech is a Shanghai-based biopharmaceutical company specializing in the development of mRNA therapeutics and advanced lipid nanoparticle (LNP) delivery systems. Founded in 2020, the company has developed a proprietary LNP platform that enables precise, organ-specific delivery, including both hepatic and extra-hepatic targeting. Its research pipeline is primarily focused on infectious disease vaccines, cancer immunotherapies, and treatments for rare genetic disorders. By addressing the technical challenges of nucleic acid delivery, Rongcan Biotech aims to provide innovative solutions for significant unmet medical needs globally.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on RongCan (Shanghai) Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RongCan (Shanghai) Biotech.

Explore the full profile